Date Title Description PDF
16 Jul 2021 On Corporate Governance ROVI announces the appointment of Juan López-Belmonte Encina as Chairman of the Company   Download
22 Jun 2021 On significant placements in financial instruments Bestinver announces the beginning of an accelerated book build process of up to a 3% of the share capital of Laboratorios Rovi, S.A. Download
22 Jun 2021 On significant placements in financial instruments Hereby inform of the completion of the private placement package. The amount of the Placement amounted to a total of 87.88 million euros, being the unit selling price of 52.25 euros per share. Download
29 Apr 2021 On business and financial situation The Company informs about the increase of its fill-finish capacity for the manufacture of Moderna’s COVID-19 vaccine outside the United States.     Download
12 Apr 2021 On business and financial situation The Company releases the press release related to its participation in the manufacture of the active substance of Moderna’s COVID-19 vaccine. Download

Pages

Date Title Description PDF
15 Feb 2022 On business and financial situation ROVI has announced that the European Commission has authorised the marketing of Okedi® for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone. Download
14 Feb 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 7 February 2022 and 11 February 2022 Download
07 Feb 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 31 January 2022 and 4 February 2022 Download
31 Jan 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 24 January 2022 and 28 January 2022 Download
24 Jan 2022 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 17 January 2022 and 21 January 2022 Download

Pages

Date Title Description PDF
10 May 2018 Otros sobre negocio y situación financiera Update pivotal PRISMA-3 study of DORIA® (Risperidone ISM®) Download
25 Apr 2018 Información sobre resultados ROVI releases the press release related to the 2018 first quarter financial results Download
25 Apr 2018 Convocatorias y acuerdos de Juntas y Asambleas generales ROVI informs about the call for the 2018 Ordinary General Shareholders Meeting Download
25 Apr 2018 Información sobre resultados ROVI releases the 2018 first quarter results presentation Download
04 Apr 2018 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted in the first quarter of 2018 Download

Pages